Lilly to present oncology data at ASCO 2026 meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Needham Starts NeoVolta (NEOV) at Buy
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- S&P 500 ends lower; chips tumble and Moderna rallies
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026 5:00 PM EDTPhase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program
Investigator-initiated study of Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma also selected for the Plenary Session
Kelonia Therapeutics, which Lilly has agreed to acquire, will present updated data for its BCMA-targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myelomaÂ
Additional Lilly presentations include the first clinical results for an investigational ADC targeting Nectin-4 in patients with... More
